Sphingolipid Metabolism Is Dysregulated in Erythrocytes from Multiple Sclerosis Patient

Momchilova, Albena; Tsonchev, Zlatan; Hadzhilazova, Mariana; Tzoneva, Rumiana; Alexandrov, Alexander I.; Nikolakov, Dimitar; Ilieva, Viktoria; Pankov, Roumen

doi:10.7546/crabs.2020.03.17

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Covered in the last review on blood apheresis technologies [22] Membrane with silicon dioxide nanoparticles Experimental Hemodialysis [23] Membrane with ferric oxide nanoparticles Experimental Hemodialysis [24] Membrane with multi-walled carbon nanotubes Experimental Hemodialysis [25] Membrane with graphene oxide nanoparticles Experimental Hemodialysis [26,27] Not covered in the last review on blood apheresis technologies [22] Membrane with nanoscale pores made of Lavsan film irradiated by accelerated in a collider charged argon particles Clinical TPE [9,[28][29][30][31][32][33]…”

Section: Type Of Nanotechnology Type Of Research Applications Referencesmentioning

confidence: 99%

“…The nanomembrane-based TPE is a non-selective method of blood purification that removes toxic and inflammatory blood components. It consists of passing the patient's blood through several nanomembranes to filter large molecules of certain molecular weight [29][30][31][32][48][49][50]. The nanomembrane-based technology involves the use of the "Hemophenix" apparatus (Figure 4) with the ROSA nanomembrane ("Trackpore Technology", Moscow, Russia) (Figure 5).…”

Section: Nanomembrane-based Tpementioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Tonev

Momchilova

2023

Biomedicines

View full text Add to dashboard Cite

Therapeutic plasma exchange (TPE) is an efficient extracorporeal blood purification technique to remove circulating autoantibodies and other pathogenic substances. Its mechanism of action in immune-mediated neurological disorders includes immediate intravascular reduction of autoantibody concentration, pulsed induction of antibody redistribution, and subsequent immunomodulatory changes. Conventional TPE with 1 to 1.5 total plasma volume (TPV) exchange is a well-established treatment in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis and Multiple Sclerosis. There is insufficient evidence for the efficacy of so-called low volume plasma exchange (LVPE) (<1 TPV exchange) implemented either by the conventional or by a novel nanomembrane-based TPE in these neurological conditions, including their impact on conductivity and neuroregenerative recovery. In this narrative review, we focus on the role of nanomembrane-based technology as an alternative LVPE treatment option in these neurological conditions. Nanomembrane-based technology is a promising type of TPE, which seems to share the basic advantages of the conventional one, but probably with fewer adverse effects. It could play a valuable role in patient management by ameliorating neurological symptoms, improving disability, and reducing oxidative stress in a cost-effective way. Further research is needed to identify which patients benefit most from this novel TPE technology.

show abstract

Section: Type Of Nanotechnology Type Of Research Applications Referencesmentioning

confidence: 99%

Section: Nanomembrane-based Tpementioning

confidence: 99%

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Tonev

Momchilova

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Our practice of saline replacement in the removal of 700-750 mL of plasma is in agreement with the so-called nanomembrane-based TPE [58]. This innovative approach involves passing the patient's blood through several nanomembranes, aiming to filter certain large molecules [113,[143][144][145][146][147][148]. The nanomembrane-based technology involves the use of the "Hemophenix" apparatus (Figure 7) with the ROSA nanomembrane ("Trackpore Technology", Moscow, Russia) (Figure 8).…”

Section: The Role Of Tpementioning

confidence: 99%

Therapeutic Plasma Exchange and Multiple Sclerosis Dysregulations: Focus on the Removal of Pathogenic Circulatory Factors and Altering Nerve Growth Factor and Sphingosine-1-Phosphate Plasma Levels

Tonev,

Momchilova

2023

CIMB

View full text Add to dashboard Cite

Multiple sclerosis (MS) is predominantly an immune-mediated disease of the central nervous system (CNS) of unknown etiology with a possible genetic predisposition and effect of certain environmental factors. It is generally accepted that the disease begins with an autoimmune inflammatory reaction targeting oligodendrocytes followed by a rapid depletion of their regenerative capacity with subsequent permanent neurodegenerative changes and disability. Recent research highlights the central role of B lymphocytes and the corresponding IgG and IgM autoantibodies in newly forming MS lesions. Thus, their removal along with the modulation of certain bioactive molecules to improve neuroprotection using therapeutic plasma exchange (TPE) becomes of utmost importance. Recently, it has been proposed to determine the levels and precise effects of both beneficial and harmful components in the serum of MS patients undergoing TPE to serve as markers for appropriate TPE protocols. In this review we discuss some relevant examples, focusing on the removal of pathogenic circulating factors and altering the plasma levels of nerve growth factor and sphingosine-1-phosphate by TPE. Altered plasma levels of the reviewed molecular compounds in response to TPE reflect a successful reduction of the pro-inflammatory burden at the expense of an increase in anti-inflammatory potential in the circulatory and CNS compartments.

show abstract

“…Our experience in the TPE treatment of MS exclusively involves the use of nanomembrane-based TPE (Figure 6) [17]. This innovative method involves passage of the patient's blood through nanomembranes designed to filter out definite molecules [18,142,[160][161][162][163][164]. There are pores in the nanomembrane with a diameter of 30-50 nm, which allow the filtration of molecules with a molecular weight below 40 kDa.…”

Section: The Role Of Tpe As An Os Modulatormentioning

confidence: 99%

“…The device has a volume of up to 70 mL [165]. The most widely used replacement is saline (NaCl 0.9), which is cheap and has no adverse effects, even when 25% of the circulating plasma is replaced [162]. The use of saline to replace the removed plasma is in agreement with the so-called low-volume plasma exchange (LVPE), which ranges from 350 mL to 2 l plasma volume removal for each separate procedure [166][167][168][169].…”

Section: The Role Of Tpe As An Os Modulatormentioning

confidence: 99%

Oxidative Stress and the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Pathway in Multiple Sclerosis: Focus on Certain Exogenous and Endogenous Nrf2 Activators and Therapeutic Plasma Exchange Modulation

Tonev,

Momchilova

2023

IJMS

View full text Add to dashboard Cite

The pathogenesis of multiple sclerosis (MS) suggests that, in genetically susceptible subjects, T lymphocytes undergo activation in the peripheral compartment, pass through the BBB, and cause damage in the CNS. They produce pro-inflammatory cytokines; induce cytotoxic activities in microglia and astrocytes with the accumulation of reactive oxygen species, reactive nitrogen species, and other highly reactive radicals; activate B cells and macrophages and stimulate the complement system. Inflammation and neurodegeneration are involved from the very beginning of the disease. They can both be affected by oxidative stress (OS) with different emphases depending on the time course of MS. Thus, OS initiates and supports inflammatory processes in the active phase, while in the chronic phase it supports neurodegenerative processes. A still unresolved issue in overcoming OS-induced lesions in MS is the insufficient endogenous activation of the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) pathway, which under normal conditions plays an essential role in mitochondria protection, OS, neuroinflammation, and degeneration. Thus, the search for approaches aiming to elevate endogenous Nrf2 activation is capable of protecting the brain against oxidative damage. However, exogenous Nrf2 activators themselves are not without drawbacks, necessitating the search for new non-pharmacological therapeutic approaches to modulate OS. The purpose of the present review is to provide some relevant preclinical and clinical examples, focusing on certain exogenous and endogenous Nrf2 activators and the modulation of therapeutic plasma exchange (TPE). The increased plasma levels of nerve growth factor (NGF) in response to TPE treatment of MS patients suggest their antioxidant potential for endogenous Nrf2 enhancement via NGF/TrkA/PI3K/Akt and NGF/p75NTR/ceramide-PKCζ/CK2 signaling pathways.

show abstract

Sphingolipid Metabolism Is Dysregulated in Erythrocytes from Multiple Sclerosis Patient

Cited by 3 publications

References 0 publications

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Therapeutic Plasma Exchange and Multiple Sclerosis Dysregulations: Focus on the Removal of Pathogenic Circulatory Factors and Altering Nerve Growth Factor and Sphingosine-1-Phosphate Plasma Levels

Oxidative Stress and the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Pathway in Multiple Sclerosis: Focus on Certain Exogenous and Endogenous Nrf2 Activators and Therapeutic Plasma Exchange Modulation

Contact Info

Product

Resources

About